Clinical Trials
64 trialsNCT07570173 2026-06-05
MK-1045-005
Merck Sharp & Dohme LLC
Phase 2/3 Recruiting
NCT05977998 2026-05-22
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03805932 2026-05-19
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT04432597 2026-05-18
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT04165096 2026-05-13
MK-3475-01C
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT06043323 2026-05-06
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04268498 2026-03-24
ADVANCE
University of Miami
Phase 2 Active not recruiting
NCT03258593 2026-03-17
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT05896228 2026-03-11
Iber-KDd
University of Miami
Phase 2 Recruiting
NCT02858310 2026-03-09
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT03913559 2026-02-12
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01391962 2026-02-02
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT04681105 2026-01-28
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
City of Hope Medical Center
Phase 1 Completed
NCT07358689 2026-01-22
Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06207305 2026-01-13
A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05704049 2025-12-29
IZALCO
Sanofi
Phase 2 Active not recruiting
NCT04270409 2025-12-12
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Sanofi
Phase 3 Active not recruiting
NCT02473042 2025-12-05
Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)
M.D. Anderson Cancer Center
Phase NA Completed
NCT02356159 2025-09-30
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT03493945 2025-09-30
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT04862585 2025-08-20
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
Ohio State University Comprehensive Cancer Center
Phase 2/3 Completed
NCT03324113 2025-08-05
Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors
Sanofi
Phase 1 Completed
NCT00840853 2025-07-09
MULTIPRAT
Baylor College of Medicine
Phase 1 Active not recruiting
NCT01059786 2025-06-12
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT03448393 2025-06-04
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03554473 2025-05-09
M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT03107182 2025-05-06
OPTIMA-II
University of Chicago
Phase 2 Completed
NCT01998971 2025-04-25
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT04599634 2025-02-04
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT06704620 2024-12-16
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Not yet recruiting
NCT03030417 2024-12-10
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04580121 2024-06-03
A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
Hoffmann-La Roche
Phase 1 Completed
NCT04846348 2024-04-25
Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis
Mayo Clinic
Phase 2 Terminated
NCT05013437 2024-04-02
AHCT
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Withdrawn
NCT04840615 2024-02-02
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT04308837 2023-11-14
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation
Icahn School of Medicine at Mount Sinai
Phase 2 Unknown
NCT04660799 2023-10-12
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 2 Completed
NCT04189588 2023-10-06
versus
TerSera Therapeutics LLC
Phase 2 Completed
NCT03330028 2023-04-21
Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
M.D. Anderson Cancer Center
Phase 1 Completed
NCT05298683 2022-03-28
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
Hellenic Society of Hematology
Phase 2 Unknown
NCT02999633 2022-03-21
ISLAY
Sanofi
Phase 2 Terminated
NCT01455389 2022-03-02
TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
Genprex, Inc.
Phase 1/2 Terminated
NCT01392183 2021-09-20
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00324467 2021-07-22
LYTPET
British Columbia Cancer Agency
Phase 2 Unknown
NCT04237090 2020-10-12
PREMED-F1
Ciusss de L'Est de l'Île de Montréal
Phase 3 Completed
NCT00185692 2019-12-04
Allogeneic Transplantation From Related Haploidentical Donors
Stanford University
Phase 2 Completed
NCT02648490 2019-07-30
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers
Henlix, Inc
Phase 1 Completed
NCT02606994 2019-02-06
TPvsM
Oral Defense, LLC
Phase 2 Terminated
NCT01332630 2018-09-20
TPI 287 in Breast Cancer Metastatic to the Brain
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01985126 2018-06-25
An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD
Janssen Research & Development, LLC
Phase 2 Completed